文献速递白血病造血干细胞移植与细胞治疗

E2A-PBX1阳性B-ALL患者十年临床结局与基因组图谱

The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: A 10-year retrospective study.
PubMed 文献 · Am J Hematol · 2021-09-04

该研究回顾性分析2009至2019年3164例B-ALL中137例E2A-PBX1阳性患者,5年OS和DFS分别为68.6%和61.0%。年龄、诱导化疗后MRD水平是独立危险因素;青少年/成人首次完全缓解期行异基因造血干细胞移植可显著改善预后。

要点

  • 年龄和诱导后MRD水平是E2A-PBX1阳性B-ALL的独立预后因素。
  • 青少年/成人CR1期行allo-HSCT可显著改善5年OS、DFS和CIR。
  • 诊断时多亚克隆及DNA修复基因突变提示不良预后。

核心结论

  • 年龄、MRD水平和DNA修复基因突变与E2A-PBX1阳性B-ALL结局相关。
  • Allo-HSCT尤其单倍体HSCT可改善青少年/成人患者预后。

研究设计与样本

  • 回顾性分析2009至2019年3164例B-ALL中137例E2A-PBX1阳性患者。

主要发现

  • 全队列5年OS为68.6%,5年DFS为61.0%。
  • 年龄与DFS(p=0.037)和CIR(p=0.005)相关。
  • 诱导化疗后MRD与OS(p=0.020)、DFS(p=0.002)和CIR(p=0.006)相关。
  • 青少年/成人CR1期allo-HSCT显著改善5年OS(p<0.001)、DFS(p<0.001)和CIR(p<0.001)。
  • 青少年/成人中单倍体HSCT较HLA相合HSCT降低CIR(p=0.017)。

关键数值与推荐

  • PBX1、PAX5、CTCF和SETD2突变、AKT3扩增及CDKN2A/B缺失在全队列中常见。
  • 诊断时多亚克隆患者3年DFS(p=0.010)和CIR(p=0.021)倾向不良。
  • DNA修复基因突变的白血病克隆呈侵袭性和治疗难治表型。

临床怎么用

  • 对E2A-PBX1阳性B-ALL应评估年龄和诱导后MRD以分层预后。
  • 青少年/成人患者可考虑CR1期行allo-HSCT,单倍体HSCT或可降低复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical outcomes and genomic features of E2A-PBX1 (TCF3-PBX1)-positive B-cell acute lymphoblastic leukemia (B-ALL) patients remain unclear. A total of 137 patients carrying E2A-PBX1 among 3164 B-ALL patients between 2009 and 2019 were retrospectively analyzed. The 5-year overall survival (OS) and disease-free survival (DFS) rates of the whole cohort were 68.6% and 61.0%, respectively. Age [DFS, p = 0.037; cumulative incidence of relapse (CIR), p = 0.005] and the level of minimal residual disease (MRD) after induction chemotherapy (OS, p = 0.020; DFS, p = 0.002; CIR, p = 0.006) were independent risk factors. In adolescents/adults, allogeneic hematopoietic stem cell transplantation (allo-HSCT) at first complete remission (CR1) significantly improved the 5-year prognosis (OS, p < 0.001; DFS, p < 0.001; CIR, p < 0.001). Haploidentical HSCT decreased the CIR compared with human leukocyte antigen-matched HSCT in adolescents/adults (p = 0.017). Mutations in PBX1, PAX5, CTCF and SETD2, amplification of AKT3, and deletion of CDKN2A/B were common in the total cohort, while transcriptome differences were found in the cell cycle, nerve growth factor (NGF) signaling pathway and transcriptional regulation by TP53 between adolescents/adults and children. Patients with multiple subclones at diagnosis tended to have unfavorable 3-year prognoses (DFS, p = 0.010; CIR, p = 0.021). Leukemia clones with DNA repair gene mutations showed aggressive and treatment-refractory phenotypes in this subtype of ALL. Our study indicated that age, the level of MRD and DNA repair gene mutations were associated with E2A-PBX1-positive B-ALL outcomes. Allo-HSCT, especially haploidentical HSCT, could improve the prognosis of adolescent/adult patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Zhou B, Chu X, Tian H, et al. The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: A 10-year retrospective study. Am J Hematol. 2021. PMID: 34406703. doi:10.1002/ajh.26324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。